Content
Search
Navigation
Sitemap
About us
About us
Who we are
Our model
Data driven investment process
Our purpose, culture and values
Our history
Our people
Our people
Board of directors
Portfolio
Portfolio
Portfolio data
Cell therapy
Overview
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
Gene therapy
Overview
Freeline Therapeutics
AGTC
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Kesmalea Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
Sustainability
Message from Chair, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Sustainability within the Syncona portfolio
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona TCFD disclosure
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and Insights
Investors
Investors
Investment proposition
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Portfolio data
Browse all portfolio data news
Search
Latest portfolio data news
Show news from
all companies
all companies
all Cell therapy companies
Autolus
all Gene therapy companies
all Biologics companies
all Small molecule companies
Clear filters
03.11.22
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
Cell therapy
Autolus
13.12.21
Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
Cell therapy
Autolus
01.09.21
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
Operating News
Cell therapy
Autolus
30.11.20
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
Operating News
Cell therapy
Autolus
12.06.20
Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress
Operating News
Cell therapy
Autolus
29.05.20
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
Operating News
Cell therapy
Autolus
Load more
Close menu
About us
About us
Who we are
Our model
Data driven investment process
Our purpose, culture and values
Our history
Our people
Our people
Board of directors
Portfolio
Portfolio
Portfolio data
Cell therapy
Overview
Autolus
Achilles Therapeutics
Quell Therapeutics
Resolution Therapeutics
Clade Therapeutics
Gene therapy
Overview
Freeline Therapeutics
AGTC
SwanBio Therapeutics
Purespring Therapeutics
Biologics
Overview
Anaveon
Small molecule
Overview
OMass Therapeutics
Kesmalea Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
Sustainability
Message from Chair, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Sustainability within the Syncona portfolio
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona TCFD disclosure
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and Insights
Investors
Investors
Investment proposition
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search